Astellas Estimates Lower Sales and Income For Fiscal Year 2008
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma released financial results May 13 for fiscal year 2007 and forecasts for 2008. The net sales for fiscal year 2008 ending March 31, 2009 is estimated to be ¥962 billion, a decrease of 1.1 percent compared to FY 2007, and operating income and net income are ¥232 billion and ¥159 billion, a decrease of 15.9 percent and 10.4 percent, respectively. Astellas cites reasons for the decrease as appreciation of the yen and an increase in research and development expenses, including an $80 million upfront payment to American company CoMentis for rights to the company's beta-secretase inhibitor program for Alzheimer's disease . (Click here for more - Japanese language
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.